Home Ad Exchange News Apple Music And Amazon’s Quid Pro Quo; Pfizer And Glaxo’s Bet On Consumer Health

Apple Music And Amazon’s Quid Pro Quo; Pfizer And Glaxo’s Bet On Consumer Health

SHARE:

Here’s today’s AdExchanger.com news round-up… Want it by email? Sign up here.

The Trillionaire Club

The campaign to promote Apple Music’s integration with Amazon Alexa-enabled devices is a biggie: top billing and a special tab for the Alexa app atop the App Store, promotions in the Apple Music app and push notifications to Apple Music subscribers. The push notification was a particularly aggressive move, writes MacStories, since promotional push notifications are against App Store guidelines. It’s a nice boost for Amazon, though. Apple is implying that integrating with Alexa is a core upgrade, like a developer update, rather than a marketing play. More. Apple and Amazon have been in an awkward dance lately. After years of frostiness, Apple became an official seller on Amazon last month, which gave Amazon a reason to squash third-party Apple product resellers. Although Amazon excludes HomePods, the Apple Music/Alexa partnership would still prove quite fruitful. Over the Thanksgiving holiday, Apple was the second-largest advertiser on Amazon (after Amazon, natch) and actually surpassed Amazon as the No. 1 brand for organic searches, according to data from the Amazon specialist ad tech company Downstream.

Take Your Medicine

GlaxoSmithKline and Pfizer will merge their consumer product divisions into a joint venture next year, with the British GlaxoSmithKline owning 68% and Pfizer owning the remainder. There’s also a plan to IPO within five years. If approved by shareholders, the joint venture will become the largest over-the-counter brand operator in the world, The New York Times reports. It’ll also transform two big fish into another true CPG brand whale. It makes sense for GSK and Pfizer to focus on their prescription drug businesses, which have higher growth potential and are increasingly divergent businesses, than to try and be consumer brand operators. Over-the-counter products such as vitamins and supplements, Advil, Nicorette, Tums and Aquafresh (all in the joint venture’s portfolio) face new competition from direct-to-consumer brands, whereas prescription meds seem like a safe bet. “But such concentration comes with risks, given that prescription drugs are costly to develop and are subject to boom-and-bust cycles in which consumer products can provide some insulation.” More.

Slap On The Wrist

Facebook and Google are being fined a collective $455,000 for violating campaign finance law in Washington. In June, the state accused both platforms of failing to keep proper records of who was buying campaign ads on their sites, The Washington Post reports. Google will pay $217,000 and Facebook will pay $238,000 for disobeying state law on political ad transparency. It’s less than a drop in the bucket for both companies, but also an indicator that regulators’ fuses are growing short. “Whether you are a small-town newspaper or a large corporation, Washington’s political advertising disclosure laws apply to everyone,” says Washington state Attorney General Bob Ferguson in a statement. More. Meanwhile, the District of Columbia filed a lawsuit on Wednesday against Facebook for violating consumer protection laws by misleading users about their data security during the Cambridge Analytica scandal. More at Bloomberg.

But Wait, There’s More!

You’re Hired!

Must Read

In 2019, Google moved to a first-price auction and also ceded its last look advantage in AdX, in part because it had to. Most exchanges had already moved to first price.

Unraveling The Mystery Of PubMatic’s $5 Million Loss From A “First-Price Auction Switch”

PubMatic’s $5 million loss from DV360’s bidding algorithm fix earlier this year suggests second-price auctions aren’t completely a thing of the past.

A comic version of former News Corp executive Stephanie Layser in the courtroom for the DOJ's ad tech-focused trial against Google in Virginia.

The DOJ vs. Google, Day Two: Tales From The Underbelly Of Ad Tech

Day Two of the Google antitrust trial in Alexandria, Virginia on Tuesday was just as intensely focused on the intricacies of ad tech as on Day One.

A comic depicting Judge Leonie Brinkema's view of the her courtroom where the DOJ vs. Google ad tech antitrust trial is about to begin. (Comic: Court Is In Session)

Your Day One Recap: DOJ vs. Google Goes Deep Into The Ad Tech Weeds

It’s not often one gets to hear sworn witnesses in federal court explain the intricacies of header bidding under oath. But that’s what happened during the first day of the Google ad tech-focused antitrust case in Virginia on Monday.

Privacy! Commerce! Connected TV! Read all about it. Subscribe to AdExchanger Newsletters
Comic: What Else? (Google, Jedi Blue, Project Bernanke)

Project Cheat Sheet: A Rundown On All Of Google’s Secret Internal Projects, As Revealed By The DOJ

What do Hercule Poirot, Ben Bernanke, Star Wars and C.S. Lewis have in common? If you’re an ad tech nerd, you’ll know the answer immediately.

shopping cart

The Wonderful Brand Discusses Testing OOH And Online Snack Competition

Wonderful hadn’t done an out-of-home (OOH) marketing push in more than 15 years. That is, until a week ago, when it began a campaign across six major markets to promote its new no-shell pistachio packs.

Google filed a motion to exclude the testimony of any government witnesses who aren’t economists or antitrust experts during the upcoming ad tech antitrust trial starting on September 9.

Google Is Fighting To Keep Ad Tech Execs Off the Stand In Its Upcoming Antitrust Trial

Google doesn’t want AppNexus founder Brian O’Kelley – you know, the godfather of programmatic – to testify during its ad tech antitrust trial starting on September 9.